You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel SCD1 inhibitors for treatment of cancer
SBC: MODULATION THERAPEUTICS, INC. Topic: 102DESCRIPTION provided by applicant Metastatic clear cell renal cell carcinoma mccRCC is an incurable cancer with a year survival of less than for which novel therapeutic agents need to be developed urgently It is notoriously resistant to chemotherapy and radiation Although molecularly targeted therapies have led to an improvement in survival the benefit is rather limited due to event ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
High-potency nitro antimicrobials for topical treatment of trichomoniasis
SBC: DESIGNMEDIX, INC. Topic: RDESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the world and million cases in the U S In addition to infections of the urogenital tract trichomoniasis increases the risk of adverse pregnancy outcomes and HIV transmission and increases the incidence ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: NIAIDDESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Peripheral Nerve-on-a-chip for Predictive Preclinical Pharmaceutical Testing
SBC: AXOSIM, INC. Topic: NCATSDESCRIPTION provided by applicant The drug development pipeline is plagued by unacceptable rates of attrition due in large part to toxicities that are not identified in pre clincal stages of development The ability to de risk lead compounds during pre clinical development with advanced andquot organoid on a chipandquot technologies show tremendous promise Chemotherapeutics in particular whi ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists
SBC: Bohemica Pharmaceuticals, LLC Topic: 100DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Mutation Enriched Targeted Re Sequencing
SBC: TRANSGENOMIC, INC. Topic: 103DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Stabilization of Influenza Vaccine by Silica-Coating
SBC: STONESTABLE, INC. Topic: NIAIDThe goal of this Phase I STTR grant proposal is to stabilize live attenuated influenza vaccine LAIV using a temporary silica coating that is removed in vivo In so doing we will establish a broader technology to eliminate the cold chain required for transport of heat and cold labile vaccines Many vaccines are unstable under ambient environmental conditions Currently vaccines are either stabil ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Cognitive Change Battery: An Assessment for Serial Administration
SBC: COGMETRIC LLC Topic: NIAABSTRACT Detecting change in neuropsychological functioning over time is critical for proper diagnosis and management of many neurological psychiatric and psychological conditions It is well documented that most commonly used cognitive assessments produce significant retest effects such as practice and regression to the mean effects Retest effects can cause substantial changes in test score ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers
SBC: NAJIT TECHNOLOGIES INC Topic: NIAIDDESCRIPTION provided by applicant Peptide conjugated phosphorodiamidate morpholino oligomers PPMO are single stranded nucleic acid analogs able to modulate gene expression through steric blocking of complementary RNA PPMO are composed of two components an antisense morpholino oligomer cargo covalently conjugated to a cell penetrating delivery peptide PPMO are completely nuclease resistant ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis
SBC: Sanguine Diagnostics And Therapeutics, Inc. Topic: 103ABSTRACT Pancreatic cancer PC is an extremely aggressive malignancy with one of the worst prognoses of all cancers with a median survival of less than one year and an overall year survival of andlt With marked resistance to chemo and radiotherapies surgery is the only curative option In patients with localized disease and no lymph node or extra pancreatic metastases complete surgical ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health